



DIPNA PHARMACHEM LIMITED

CIN :- U24100GJ2011PTC066400 GSTN :- 24AADCD9404F1ZY

Date: 10th July, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir / Ma'am,

Subject: Submission of Audited Financial Results for the half and Year ended on 31st March, 2023 along with Auditor's Report and Declaration

Ref: Security Id: DPL / Code: 543594

In reference to captioned subject and pursuant to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Audited Financial Results for the Half and Financial Year ended on 31st March, 2023 along with Auditor's Report and Declaration.

Kindly take the same on your record and oblige us.

Thanking You.

For, Dipna Pharmachem Limited **PHARMACHEM LIMITED**

Keyur Shah
Managing Director
DIN: 03167258

Office Address:-
A-211, Siddhi Vinayak Tower,
B/H DCP Office, Off. S.G. Highway,

Godown Address :-
C-124, Sagar Estate,
Nr Relief Hotel, S.G. Road,

☎ 079-66170806 / 07
✉ dharachem99@yahoo.in /
info@dipnapharmachem.com

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

REGD. OFFICE: A-211 , Siddhi Vinayk Tower, B/h DCP Office, Makarba, Ahmedabad-380051

(Rs. In Lakhs Except EPS)

Particulars	Year Ended	
	31.03.2023	31.03.2022
	(Audited)	(Audited)
	Rs. (In Lacs)	Rs. (In Lacs)
I. EQUITY AND LIABILITIES		
1 Shareholders Funds		
(a) Share Capital	1,197.00	3.50
(b) Reserves and Surplus	1,238.81	170.35
(c) Money Received Against Share Warrants	-	-
Total Shareholders Funds	2,435.81	173.85
3 Non-Current Liabilities		
(a) Long-Term Borrowings	1,417.70	332.61
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long Term Liabilities	-	-
(d) Long-Term Provisions	-	-
Total Non Current Liabilities	1,417.70	332.61
4 Current Liabilities		
(a) Short-Term Borrowings	173.06	686.28
(b) Trade Payables		
i) Total Outstanding dues of micro enterprise and small	1,690.41	386.23
ii) Total Outstanding dues of creditors other than micro		
enterprise and small enterprise	1,937.85	1,916.77
(c) Other Current Liabilities	13.90	86.97
(d) Short-Term Provisions	87.25	40.25
Total Current Liabilities	3,902.47	3,116.50
TOTAL >>>>	7,755.97	3,622.96
II. ASSETS		
Non-Current Assets		
1 (a) Fixed Assets		
(i) Tangible Assets	3.96	4.12
(ii) Intangible Assets	-	-
(iii) Capital Work-In-Progress	-	-
(iv) Intangible Assets under Development	-	-
(b) Non-Current Investments	-	-
(c) Deferred Tax Assets (Net)	0.06	-
(d) Long-Term Loans and Advances	-	-
(e) Other Non-Current Assets	-	-
Total Non Current Assets	4.01	4.12
2 Current Assets		
(a) Current Investments		-
(b) Inventories	1,894.31	630.36
(c) Trade Receivables	2,853.18	2,697.48
(d) Cash and Cash Equivalents	569.23	20.87
(e) Short-Term Loans and Advances	-	-
(f) Other Current Assets	2,435.25	270.14
Total Current Assets	7,751.96	3,618.84
TOTAL >>>>	7,755.97	3,622.96

Place: Ahmedabad

Date: 10-07-2023



For, Dipna Pharmachem Limited

Keyur Shah

Managing Director

DIN: 03167258

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

REGD. OFFICE: A-211 , Siddhi Vinayk Tower, B/h DCP Office, Makarba, Ahmedabad-380051

Particulars	6 Months Ended		(Rs. In Lakhs Except EPS)		
	31.03.2023 (Audited)	30.09.2022 (Unaudited)	31.03.2022 (Audited)	For the Period Ended 31st March 2023	For the Period Ended 31st March 2022
	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)	Rs. (In Lacs)
I. Revenue from Operations	5132.35	4860.37	4350.54	9992.72	7,275.55
II Other Income	0.63	-	0.89	0.63	1.04
Total Revenue (I + II)	5,132.98	4,860.37	4,351.43	9,993.35	7,276.59
III. Expenses:					
Purchases of material	5227.81	5585.19	3786.85	10813.00	6,766.67
Changes in Inventories	-329.00	-934.95	293.40	-1263.95	89.15
Employee Benefits Expenses	25.20	18.30	29.18	43.50	53.54
Finance Costs	50.89	44.75	30.42	95.64	62.94
Depreciation and Amortization expense	0.70	0.47	0.31	1.17	0.62
Power and Fuel	0.08	0.22	0.06	0.30	0.11
Other Expenses	64.41	101.16	97.29	165.57	146.13
Total Expenses	5,040.08	4,815.14	4,237.51	9,855.22	7,119.16
IV. Profit before exceptional and extraordinary items and tax (III-IV)	92.90	45.23	113.92	138.13	157.43
V. Exceptional Items	-	-	-	-	-
Prior Period Expenses	-	-	-	-	-
VI. Profit Before Extraordinary Items and Tax (V - VI)	92.90	45.23	113.92	138.13	157.43
VIII. Extraordinary Items	-	-	-	-	-
IX. Profit before tax (VII- VIII)	92.90	45.23	113.92	138.13	157.43
X Tax expense:					
(1) Current tax	35.00	12.00	29.74	47.00	40.74
(2) Deferred tax	(0.06)	-	-	-0.06	-
XI Profit (Loss) for the period from continuing operations (VII-VIII)	57.96	33.23	84.18	91.19	116.69
XII Profit/(loss) from discontinuing operations	-	-	-	-	-
XIII Tax expense of discontinuing operations	-	-	-	-	-
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-
XV Profit (Loss) for the period (XI + XIV)	57.96	33.23	84.18	91.19	116.69
XVI BALANCE BROUGHT FROM PREVIOUS YEAR	-	-	-	-	-
XVII BALANCE CARRIED TO BALANCE SHEET	57.96	33.23	84.18	91.19	116.69
XVIII Details of equity Share Capital					
Paid Up Equity Share Capital	-	1,197.00	3.50	1,197.00	3.50
Face Value of equity share Capital	-	1,197.00	3.50	1,197.00	3.50
XVIII Earnings per equity share:					
(1) Basic	260.27	0.28	240.51	260.55	333.39
(2) Diluted	260.27	0.28	240.51	260.55	333.39

Notes :

Notes:-

- The above Audited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 10th July, 2023
- The Statutory Auditors of the Company have carried out the Statutory Audit of the above financial results of the Company and have expressed an unmodified opinion on these Results.
- There are no investor complaints received/pending as on March 31, 2023
- Previous year/s/ period figures have been regrouped/ reclassified/ restated, wherever necessary to confirm to classification of current year/period.

Place: Ahmedabad

Date: 10-07-2023



For, Dipna Pharmachem Limited

Keyur Shah

Managing Director

DIN: 03167258

DIPNA PHARMACHEM LIMITED

CIN: L24100GJ2011PLC066400

REGD. OFFICE: A-211 , Siddhi Vinayk Tower, B/h DCP Office, Makarba, Ahmedabad-380051

	(Rs. In Lakhs Except EPS)	
	Rs. (In Lacs)	
	For the Period Ended 31st March 2023	For the Year Ended 31st March,2022
Cash flows from operating activities		
Profit before taxation	138.13	157.43
Adjustments for:		
Depreciation	1.17	0.62
Investment income	-	-
Deferred tax Liability	-	-
Interest expense	95.64	60.57
Profit / (Loss) on the sale of property, plant & equipment	-	-
Working capital changes:		
(Increase) / Decrease in trade and other receivables	(155.70)	(1,202.70)
(Increase) / Decrease in inventories	(1,263.95)	89.15
(Increase) / Decrease in Short Term Loan & Advance	-	-
(Increase) / Decrease in Other Current Assets	(2,165.11)	(34.46)
Increase / (Decrease) in Trade payables	1,299.19	1,250.68
Increase / (Decrease) in Short term Provisions	-	-
Increase / (Decrease) in Other Current Liabilities	-	-
	(2,050.63)	321.28
Cash generated from operations	47.00	40.74
Interest paid	-	-
Income taxes paid	-	-
Dividends paid	-	-
Net cash from operating activities	(2,097.63)	280.54
Cash flows from investing activities		
Business acquisitions, net of cash acquired	-	-
Purchase of property, plant and equipment	(1.01)	(0.68)
Proceeds from sale of equipment	-	-
Acquisition of portfolio investments	-	-
Investment income	-	-
Net cash used in investing activities	(1.01)	(0.68)
Cash flows from financing activities		
Proceeds from issue of share capital including premium	2,170.82	-
Interest Paid	(95.64)	(60.57)
Net Proceeds from borrowings	571.87	(223.75)
Net cash used in financing activities	2,647.05	(284.32)
Net increase in cash and cash equivalents	548.42	(4.45)
Cash and cash equivalents at beginning of period	20.87	25.32
Cash and cash equivalents at end of period	569.28	20.87

Place: Ahmedabad
Date: 10-07-2023

For, Dipna Pharmachem Limited


 Keyur Shah
 Managing Director
 DIN: 03167258



Independent Auditor's Report on Audited Standalone half yearly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF
DIPNA PHARMACHEM LIMITED**

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying half yearly standalone financial results of DIPNA PHARMACHEM LIMITED ("the company") for the half year ended on 31/03/2023 (which is derived as a balancing figures of the difference between audited figures in respect of the financial year ended on 31/03/2023 and the published unaudited year to date figures up to the half year of the current financial year ended on 30/09/2022 which were subject to limited review by us) and the year to date results for the period from 01/04/2022 to 31/03/2023 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the half year ended 31/03/2023 as well as the year to date results for the period from 01/04/2022 to 31/03/2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in





DEVADIYA & ASSOCIATES

CHARTERED ACCOUNTANTS

accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

These standalone half yearly financial results (which is derived as a balancing figures of the difference between audited figures in respect of the financial year ended on 31/03/2023 and the published unaudited year to date figures up to the half year of the current financial year ended on 30/09/2022 which were subject to limited review) as well as the year to date standalone financial results have been prepared on the basis of the audited annual financial statements for the year ended on 31/03/2023. The Company's Board of Directors is responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.





Auditor's Responsibilities for the Audit of the Standalone Financial Results


Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and

are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.






DEVADIYA & ASSOCIATES
CHARTERED ACCOUNTANTS

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all Relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For, DEVADIYA & ASSOCIATES
CHARTERED ACCOUNTANT
FRN: 123045W



(CA SANJAY DEVADIYA)
PARTNER
Membership No. 112495
Date: 10/07/2023
Place: AHMEDABAD
UDIN: 23112495BGYWCW7444



DIPNA PHARMACHEM LIMITED

CIN :- U24100GJ2011PTC066400 GSTN :- 24AADCD9404F1ZY

Date: 10th July, 2023

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir / Ma'am,

**Subject: Declaration in respect of Unmodified Opinion on Audited Financial Result
for the Financial Year ended on 31st March, 2023**

Ref: Security Id: DPL / Code: 543594

We hereby declared that the Statutory Auditor of the Company, M/s. Devadiya & Associates., Chartered Accountants, Ahmedabad has issued Audit Report with Unmodified Opinion on Audited Financial Result for the half Year and Financial Year ended as on 31st March, 2023.

The declaration is given in compliance to second proviso of Reg. 33(3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment), Regulations 2016, vide notification no. SEBI/LAD-NRO/GN/2016-17/001, dated 25th May, 2016.

Kindly take the same on your record and oblige us.

Thanking You.

For, Dipna Pharmachem Limited

Keyur Shah
Managing Director
DIN: 03167258